DGAP-Adhoc: biolitec has entered into a non-binding letter of intent for the acquisition of specified assets of Diomed Holdings, Inc.

biolitec AG / Letter of Intent

14.03.2008 

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------

Jena, March 14, 2008 – biolitec AG, Jena, listed in the Prime Standard of
the Frankfurt stock exchange (ISIN DE0005213409), has entered into a
non-binding letter of intent for the acquisition of certain operating
assets of Diomed Holdings, Inc., (AMEX:DIO), a leading developer and
marketer of minimally invasive medical technologies including laser
treatment for varicose veins in the USA. The senior management of both
companies anticipate a purchase price of between $6 and $7 million for
these assets.

biolitec expects to complete the asset purchase within approximately 2 to 3
months. Diomed reported revenues of $ 26 million in the fiscal year ended
December 31, 2007. After a restructuring phase biolitec expects strong
synergies due to this purchase mainly for the vein business as well as an
expansion of its own market position in the field of minimal invasive
technologies in the USA.







DGAP 14.03.2008 
---------------------------------------------------------------------------
Language:     English
Issuer:       biolitec AG
              Winzerlaer Straße 2a
              07745 Jena
              Deutschland
Phone:        +49 (0)3641 5 08-5 50
Fax:          +49 (0)3641 5 08-5 99
E-mail:       info@biolitec.de
Internet:     www.biolitec.de
ISIN:         DE0005213409
WKN:          521340
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Stuttgart, München, Hamburg, Düsseldorf
End of News                                     DGAP News-Service
---------------------------------------------------------------------------